866-997-4948(US-Canada Toll Free)

Klebsiella pneumoniae Infections - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 82 Pages

Klebsiella pneumoniae Infections - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2017, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 19 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Klebsiella pneumoniae Infections - Overview
Klebsiella pneumoniae Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Klebsiella pneumoniae Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development
Appili Therapeutics
Cellceutix Corp
Debiopharm International SA
Evaxion Biotech ApS
F. Hoffmann-La Roche Ltd
FOB Synthesis Inc
ImmunoClin Corp
Kyorin Pharmaceutical Co Ltd
Melinta Therapeutics Inc
Nosopharm SAS
Peptilogics Inc
Pfizer Inc
Phico Therapeutics Ltd
Sarepta Therapeutics Inc
Shionogi & Co Ltd
Soligenix Inc
Syntiron LLC
Tetraphase Pharmaceuticals Inc
Klebsiella pneumoniae Infections - Drug Profiles
Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASN-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-1503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-824 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-1807 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cefiderocol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Debio-1454 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dusquetide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EBX-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FSI-1671 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FSI-1686 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNeg Snare - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interleukin-22 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Klebsiella pneumoniae vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Klebsiella pneumoniae vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Klebsiella pneumoniae vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirandamycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOSO-95179 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Onc-72 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OTP-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PT-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RX-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXP-873 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial and Fungal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Klebsiella pneumoniae Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-6076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WLBU-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Klebsiella pneumoniae Infections - Dormant Projects
Klebsiella pneumoniae Infections - Discontinued Products
Klebsiella pneumoniae Infections - Product Development Milestones
Featured News & Press Releases
Apr 20, 2017: Arsanis Presents Data on ASN-300 at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Apr 11, 2017: Appili Therapeutics Receives Funding from the Government of Canada to Support Development of New Antibiotic To Treat Gram-Negative Infections
Jun 17, 2016: Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Klebsiella pneumoniae using Monoclonal Antibody Technology
Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Klebsiella pneumoniae Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Cellceutix Corp, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Debiopharm International SA, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Evaxion Biotech ApS, H1 2017
Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Klebsiella pneumoniae Infections - Pipeline by FOB Synthesis Inc, H1 2017
Klebsiella pneumoniae Infections - Pipeline by ImmunoClin Corp, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics Inc, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Peptilogics Inc, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Pfizer Inc, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Ltd, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Sarepta Therapeutics Inc, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co Ltd, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Soligenix Inc, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, H1 2017
Klebsiella pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
Klebsiella pneumoniae Infections - Dormant Projects, H1 2017
Klebsiella pneumoniae Infections - Dormant Projects, H1 2017 (Contd..1), H1 2017
Klebsiella pneumoniae Infections - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Klebsiella pneumoniae Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *